Table 1.
Common Adverse Events and Adverse Events Resulting in Treatment Discontinuation in Studies Comparing Elvitegravir-Based, Efavirenz-Based, and Atazanavir-Based Regimens
| Adverse Event | Rate of Occurrence by Treatment Regimen | |||
|---|---|---|---|---|
| Elvitegravir-Based (n = 749) | Efavirenz-Based (n = 375) | Atazanavir-Based (n = 355) | ||
| Grade 2 to 4 Adverse Eventsa | ||||
| Diarrhea | 6% | 4% | 8% | |
| Rash events | 4% | 9% | 4% | |
| Headache | 4% | 2% | 3% | |
| Bronchitis | 4% | 2% | 3% | |
| Upper respiratory infection | 4% | 4% | 3% | |
| Depression | 3% | 7% | 3% | |
| Nausea | 3% | 3% | 3% | |
| Insomnia | 2% | 3% | 2% | |
| Fatigue | 2% | 4% | 4% | |
| Herpes zoster | 2% | 1% | 3% | |
| Abnormal dreams | 0.4% | 4% | 0.3% | |
| Dizziness | 0.4% | 3% | 1% | |
| Adverse Events Leading to Treatment Discontinuation | ||||
| Renal events | 0.8% | 0% | 0.3% | |
| Rash events | 0.1% | 1.1% | 1.1% | |
| Nausea | 0.3% | 0% | 1.1% | |
| Diarrhea | 0.3% | 0% | 0.3% | |
| Pyrexia | 0.3% | 0.3% | 0% | |
| Fatigue | 0.3% | 0.3% | 0.6% | |
Elvitegravir-based group received elvitegravir/cobicistat/emtricitabine/tenofovir; efavirenzbased group received efavirenz/emtricitabine/tenofovir; atazanavir-based group received atazanavir/ritonavir plus tenofovir/emtricitabine.
a
Affecting at least 2.5% of patients in any group.
Adapted with permission from Benson et al.8